AZN : IMFINZI-based Treatment Reduces Risk Of Disease Recurrence In Lung Cancer In Phase III Trial
17/4 04:18
(RTTNews) - AstraZeneca (AZN.L, AZN) said that positive results from the AEGEAN Phase III trial showed that treatment with the company's IMFINZI (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery led to a statistical...